4-甲基氢D-天冬氨酸盐酸盐 | 22728-89-8

• 物质功能分类: 生物化工 - 氨基酸及其衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-甲基氢D-天冬氨酸盐酸盐
• 中文别名: D-天冬氨酸酸-B-甲酯盐酸盐
• 英文名称: (R)-2-amino-4-methoxy-4-oxobutanoic acid hydrochloride
• 英文别名: 4-Methyl hydrogen D-aspartate hydrochloride；(2R)-2-amino-4-methoxy-4-oxobutanoic acid;hydrochloride
• CAS: 22728-89-8
• 化学式: C₅H₉NO₄*ClH
• 分子量: 183.592
• InChiKey: QRBMPUYOGOCYDJ-AENDTGMFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.62
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  89.6
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2922509090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温和干燥环境

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-D-Asp(OMe)-OH HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-D-Asp(OMe)-OH HCl
CAS number: 22728-89-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H9NO4.ClH
Molecular weight: 183.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲基氢D-天冬氨酸盐酸盐 、 甲胺 以 水 为溶剂， 以83%的产率得到D-2-amino-3-methylaminopropionic acid
  参考文献：
  名称：

  一种便捷的制备阿扑西林钠的方法

  摘要：

  本发明公开了一种便捷的制备阿扑西林钠的方法，将D‑天冬氨酸在低温下加入到氯化亚砜和甲醇的混合液中反应制备D‑天冬氨酸甲酯盐酸盐，将其与甲胺水溶液反应可得天冬甲酰胺，将天冬甲酰胺上的伯氨基用三氟乙酰基保护，接着与羰基二咪唑形成活性混合酸酐，再与阿莫西林三乙胺盐缩合，最后在碱性条件下脱保护基和成钠盐，得到目标产物阿扑西林粗品，最后精制可得高纯度的阿扑西林钠成品。本发明具有试剂廉价易得，毒性和对环境压力小，工艺操作简洁稳定，产品纯度高等优点。

  公开号：

  CN103992337B
• 作为产物：
  描述：

  D-天门冬氨酸 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 以10.7 g (78%)的产率得到4-甲基氢D-天冬氨酸盐酸盐
  参考文献：
  名称：

  Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases

  摘要：

  式（I）中的化合物，其中W为—OH或—NHOH；X为可选择取代的杂环、NR1SO2R2、杂环烷硫基、CONR2R3或NR1COR2；Y、Z、R1-R3和n的定义如申请中所述。化合物（I）是基质降解金属蛋白酶的抑制剂，用于治疗相关疾病。

  公开号：

  US06410580B1

文献信息

• Design and preparation of serine–threonine protein phosphatase inhibitors based upon the nodularin and microcystin toxin structures: Part 2.1 Synthesis of a functionalised nodularin macrocycle and a stripped-down microcystin macrocycle
  作者：Antony B. Maude、Amit P. Mehrotra、David Gani

  DOI：10.1039/a702410j

  日期：——

  Nodularins and microcystins are complex natural isopeptidic hepatotoxins that serve as subnanomolar inhibitors of the eukaryotic serine–threonine protein phosphatases, PP1 and PP2A. In Part 1 (A. P. Mehrotra, K. L. Webster and D. Gani, J. Chem. Soc., Perkin Trans. 1, 1997, preceding paper) each of the key structural or potentially reactive motifs within each macrocycle type was assessed as a contributor towards phosphatase inhibitory efficacy and a stripped-down nodularin-type macrocycle was identified as a suitable precursor to potentially active synthetic inhibitors. Subsequently, synthetic routes to the 19-membered nodularin macrocyclic system were developed, using solution-phase chemistry, which demonstrated that only certain cyclisation protocols were viable. Here we describe an extension of this chemistry to provide a 19-membered nodularin macrocycle, cyclo-[(3R)-3-hydroxymethyl-β-Ala-( R)-Glu-α-OMe-γ-Sar-(R)-Asp- α-OMe-β-(S)-Phe-], appropriately functionalised with a hydroxymethyl group for the incorporation of lipophilic side-chains. We also demonstrate that the 25-membered microcystin macrocycle, cyclo-[β-Ala-(R)-Glu-α- OMe-γ-Sar-(R)-Ala-(S)-Leu-( R)-Asp-α-OMe-β-(S)- Phe-], can be prepared in good yield using similar protocols in which macrocyclisation is effected through the reaction of the amino group of the (2S)-phenylalanine residue with the β-pentafluorophenyl ester of the (2R)-aspartic acid residue.

  结节素和微囊藻毒素是复杂的天然同型肽肝毒素，作为真核丝氨酸-苏氨酸蛋白磷酸酶PP1和PP2A的亚纳摩尔抑制剂。在第一部分（A. P. Mehrotra, K. L. Webster和D. Gani，《化学学会杂志》，珀金斯1号，1997年，前面的论文）中，评估了每种大环类型中每个关键结构或潜在反应性基序对磷酸酶抑制效力的贡献，并确定了一个简化版的结节素型大环作为潜在活性合成抑制剂的合适前体。随后，开发了使用溶液相化学合成19元结节素大环体系的合成路线，这表明只有某些环化方案是可行的。在这里，我们描述了这种化学方法的扩展，以提供一个19元结节素大环，环状-[(3R)-3-羟甲基-β-Ala-(R)-Glu-α-OMe-γ-Sar-(R)-Asp-α-OMe-β-(S)-Phe-]，适当地带有羟甲基团以纳入亲脂性侧链。我们还证明了25元微囊藻毒素大环，环状-[β-Ala-(R)-Glu-α-OMe-γ-Sar-(R)-Ala-(S)-Leu-(R)-Asp-α-OMe-β-(S)-Phe-]，可以使用类似的方案以良好产率制备，其中大环化是通过(2S)-苯丙氨酸残基的氨基与(2R)-天冬氨酸残基的β-五氟苯酯的反应实现的。
• BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS
  申请人：QUADRIGA BIOSCIENCES, INC.

  公开号：US20150218086A1

  公开（公告）日：2015-08-06

  β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

  β-取代β-氨基酸，β-取代β-氨基酸衍生物，β-取代β-氨基酸类似物和（生物）同位素及其作为化疗药物的用途被披露。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物和（生物）同位素是选择性LAT1/4F2hc底物，并在表达LAT1/4F2hc转运蛋白的肿瘤中表现出快速摄取和保留。还披露了合成β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物的方法以及使用这些化合物治疗癌症的方法。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物在表达LAT1/4F2hc转运蛋白的肿瘤细胞中表现出选择性摄取，并在体内给予受试者后在癌细胞中积累。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物和（生物）同位素对几种肿瘤类型表现出细胞毒性。
• 一种第十因子抑制剂及其制备方法和应用
  申请人：山东凯森制药有限公司

  公开号：CN105294669B

  公开（公告）日：2019-01-22

  本发明涉及一种第十因子抑制剂及其制备方法和应用，所述第十因子抑制剂具有通式Ⅰ的结构，本发明抑制剂以alpha‑氨基酸为模板，分别通过酰胺、氨基甲酸酯、或则脲为支链形成一系列结构新颖的化合物，这类化合物可以有效地与第十因子结合，阻止血栓的形成。
• Matrix Metalloproteinase Inhibitors Containing a [(Carboxyalkyl)amino]zinc Ligand: Modification of the P1 and P2' Residues
  作者：Frank K. Brown、Peter J. Brown、D. Mark Bickett、C. Lynn Chambers、H. Geoff Davies、David N. Deaton、David Drewry、Michael Foley、Andrew B. McElroy

  DOI：10.1021/jm00031a018

  日期：1994.3

  Systematic modification of the presumed P1 side chain in a series of (carboxyalkyl)amino-based inhibitors of matrix metalloproteinases enabled identification of the 2-(1,3-dihydro-1,3-dioxo-2H-benz[f]isoindol-2-yl)ethyl group as a preferred substituent imparting potent inhibition of the enzymes collagenase and gelatinase. It was subsequently found that the P2'-P3' residues in this series could be replaced

  系统修饰一系列基质金属蛋白酶的（基于羧基烷基）氨基的抑制剂中假定的P1侧链，可以鉴定2-（1,3-二氢-1,3-二氧代-2H-苯并[f] isoindol-2作为优选的取代基的R 1-基）乙基赋予对胶原酶和明胶酶的有效抑制作用。随后发现该系列中的P2'-P3'残基可以被小的非肽残基取代，同时保持抑制能力。该系列化合物中的酰亚胺基团可以在中性条件下进行自催化水解。
• [EN] PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE L'ACIDE (R)-4-(1-(6-(4-(TRIFLUOROMÉTHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL)BENZOÏQUE OU DE SON SEL
  申请人：ROTTAPHARM BIOTECH SRL

  公开号：WO2021191062A1

  公开（公告）日：2021-09-30

  The present invention provides a process for preparing (R)-6-(tert-butoxycarbonyl)-6- azaspiro[2.5]octane-5-carboxylic acid (SM1), said process comprising the step of: iv) converting a compound of formula (VII) into a compound of formula (VIII) using a Wittig reagent in a suitable solvent; v) reacting through the Makosza reaction the compound of Formula (VIII) using bromoform and a suitable base to obtain cyclopropane compound of Formula (IX); and vi) removing bromine atoms in the presence of a reducing agent and a base in an alcoholic solvent thus obtaining (SM1). The invention relates also to a process for the conversion of the compound (SM1) for preparing (R)- 4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl) benzoic acid (IV) or a salt thereof. The salt is preferably the sodium salt, more preferably the polymorphic form A of sodium (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6- azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2θ ±0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9.

  本发明提供了一种制备(R)-6-(叔丁氧羰基)-6-氮杂螺[2.5]辛烷-5-羧酸（SM1）的方法，该方法包括以下步骤：iv）在适当的溶剂中使用威替试剂将化合物（VII）转化为化合物（VIII）；v）通过Makosza反应，使用溴仿和适当的碱反应化合物（VIII）以获得环丙烷化合物（IX）；vi）在醇溶剂中存在还原剂和碱的情况下去除溴原子，从而获得（SM1）。该发明还涉及一种将化合物（SM1）转化为制备(R)-4-(1-(6-(4-(三氟甲基)苯基)-6-氮杂螺[2.5]辛烷-5-羧氨基)环丙基)苯甲酸（IV）或其盐的方法。该盐优选为钠盐，更优选为钠的多形式A（R)-4-(1-(6-(4-(三氟甲基)苯基)-6-氮杂螺[2.5]辛烷-5-羧氨基)-环丙基)苯酸盐，其具有在角度2θ ±0.2°处的峰值的粉末XRD谱特征为4.3、5.0、5.8、6.4、7.1、8.3、8.7、12.8、15.3、15.9。